概括
在14名患者中,口服素有效治疗了Plasmodium falciparum疟疾,没有表现出心脏毒性. 这种抗疟疾药物可能比因更强,在体外观察到的最低抑制度较低.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 热带医学 热带医学
背景情况:
- 疟原 (Plasmodium falciparum) 疟疾仍然是一个重大的全球健康威胁.
- 耐药性需要开发新的有效的抗疟疾治疗方法.
- 素一直是主要的治疗方法,但其疗效受到耐药性和副作用的挑战.
研究的目的:
- 评估口服素治疗Plasmodium falciparum疟疾的疗效和安全性.
- 为了比较素和素的体外活性与Plasmodium falciparum.
主要方法:
- 在一项临床研究中,14名患者接受了口服素的治疗.
- 患者随访评估了35天的复发情况.
- 在体外培养物中,比较了素和素的最小抑制度 (MIC).
主要成果:
- 所有14名患者都获得了口服素的成功治疗.
- 十二名患者在35天内没有复发.
- 在体外研究表明,与因相比,因的MIC始终较低.
结论:
- 口服胺是一种有效的治疗Plasmodium falciparum疟疾.
- 奎尼丁显示出对这种寄生虫的潜在效力比奎宁更大.
- 需要进一步研究素在疟疾治疗中的作用.
相关概念视频
Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


